Difference between revisions of "Trazodone-escitalopram"
From Psychiatrienet
| Line 13: | Line 13: | ||
* Escitalopram is a weak inhibitor of CYP2D6, which metabolizes trazodone. | * Escitalopram is a weak inhibitor of CYP2D6, which metabolizes trazodone. | ||
* The content of trazodone in the tablet, for example 100 mg or 150 mg, determines which exact doses are given. | * The content of trazodone in the tablet, for example 100 mg or 150 mg, determines which exact doses are given. | ||
| + | {{review}} | ||
}} | }} | ||
Revision as of 14:54, 2 November 2015
| ||||||||||||||||||||||
| ||||||||||||||||||||||
Switch medication from trazodone to escitalopram.[1] [2]
Stop trazodone - Before day 1: gradually reduce dosage of trazodone to a maximum of 150 mg/day, when this dosage is > 150 mg/day.
- Day 1: reduce dosage of trazodone to 75-100 mg/day.
- Day 8: stop administration of trazodone.
Start escitalopram- A wash-out period is not necessary, but care is needed.
- Day 8: start administration of escitalopram in a normal dosage of 10 mg/day.
More information- Occurrence of serotonin syndrome is theoretically possible, so caution is necessary.
- Escitalopram is a weak inhibitor of CYP2D6, which metabolizes trazodone.
- The content of trazodone in the tablet, for example 100 mg or 150 mg, determines which exact doses are given.
- This switch is currently being reviewed.
- ↑ Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
- ↑ Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
